Celestine buys MDVN 76.23: UPDATE: Stifel Reiterates On Medivation Following Prostate Cancer Survey
In a report published Monday, Stifel analyst Joel Sendek reiterated a Buy rating on Medivation (NASDAQ: MDVN), and raised the price target from $81.00 to $83.00. In the report, Stifel noted, âBased on our survey of 40 doctors who treat prostate cancer .. ...
56 people liked this
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home